{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T01:34:32Z","timestamp":1786671272549,"version":"build-2736575974"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1097\/jcp.0b013e3181bfe13e","type":"journal-article","created":{"date-parts":[[2009,11,7]],"date-time":"2009-11-07T03:15:39Z","timestamp":1257563739000},"page":"576-583","source":"Crossref","is-referenced-by-count":38,"title":["30 Days of Continuous Olanzapine Infusion Determines Energy Imbalance, Glucose Intolerance, Insulin Resistance, and Dyslipidemia in Mice"],"prefix":"10.1097","volume":"29","author":[{"given":"Roberto","family":"Coccurello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Brina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Caprioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando","family":"Ghirardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Schepis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Moles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210128","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.","volume":"1","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"R2-11-20210128","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/1389450043490514","article-title":"Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics.","volume":"5","author":"Baptista","year":"2004","journal-title":"Curr Drug Targets"},{"key":"R3-11-20210128","first-page":"4","article-title":"The pharmacology of weight gain with antipsychotics.","volume":"62","author":"Casey","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R4-11-20210128","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200822060-00003","article-title":"Pharmacological management of atypical antipsychotic-induced weight gain.","volume":"22","author":"Baptista","year":"2008","journal-title":"CNS Drugs"},{"key":"R5-11-20210128","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0091-3057(87)90340-6","article-title":"Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved?","volume":"27","author":"Baptista","year":"1987","journal-title":"Pharmacol Biochem Behav"},{"key":"R6-11-20210128","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0014-2999(02)01816-2","article-title":"The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved?","volume":"447","author":"Baptista","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"R7-11-20210128","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.ijo.0802928","article-title":"Antipsychotic drug-induced weight gain: development of an animal model.","volume":"29","author":"Cope","year":"2005","journal-title":"Int J Obes"},{"key":"R8-11-20210128","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0006-8993(02)03616-8","article-title":"Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: Body weight, food intake, body composition, hormones and glucose tolerance.","volume":"957","author":"Baptista","year":"2002","journal-title":"Brain Res"},{"key":"R9-11-20210128","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.pnpbp.2007.09.012","article-title":"Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.","volume":"32","author":"Cooper","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R10-11-20210128","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.tpj.6500346","article-title":"cDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effects.","volume":"6","author":"Sondhi","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"R11-11-20210128","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/026988110201600402","article-title":"Characterization of olanzapine-induced weight gain in rats.","volume":"16","author":"Goudie","year":"2002","journal-title":"J Psychopharmacol"},{"key":"R12-11-20210128","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/0269881104042613","article-title":"Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats.","volume":"18","author":"Fell","year":"2004","journal-title":"J Psychopharmacol"},{"key":"R13-11-20210128","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00213-005-2224-4","article-title":"A parametric analysis of olanzapine-induced weight gain in female rats.","volume":"181","author":"Cooper","year":"2005","journal-title":"Psychopharmacology"},{"key":"R14-11-20210128","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00213-006-0368-5","article-title":"Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.","volume":"186","author":"Coccurello","year":"2006","journal-title":"Psychopharmacology"},{"key":"R15-11-20210128","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1124\/jpet.108.137240","article-title":"Olanzapine (LY170053, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno2,3-b1,5 benzodiazepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo2,1-b1,3benzothiazepine), chronic administration induces weight gain, hyperphagia, and metabolic dysregulation in mice.","volume":"326","author":"Coccurello","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"R16-11-20210128","first-page":"55","article-title":"Chronic administration of olanzapine affects behavioural satiety sequence and feeding behaviour in female mice.","volume":"13","author":"Coccurello","year":"2008","journal-title":"Eat Weight Disord"},{"key":"R17-11-20210128","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy.","volume":"305","author":"Kapur","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R18-11-20210128","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"R19-11-20210128","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/beheco\/arn020","article-title":"Time for some a priori thinking about post hoc testing.","volume":"19","author":"Ruxton","year":"2008","journal-title":"Behav Ecol"},{"key":"R21-11-20210128","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.162.1.118","article-title":"Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis.","volume":"162","author":"Graham","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R22-11-20210128","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/oby.2008.468","article-title":"The role of thermogenesis in antipsychotic drug-induced weight gain.","volume":"17","author":"Stefanidis","year":"2009","journal-title":"Obesity"},{"key":"R23-11-20210128","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jada.2005.01.005","article-title":"Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication.","volume":"105","author":"Sharpe","year":"2005","journal-title":"J Am Diet Assoc"},{"key":"R24-11-20210128","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1055\/s-2002-31521","article-title":"Decrease of energy expenditure causes weight increase in olanzapine treatment-a case study.","volume":"35","author":"Virkkunen","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"R25-11-20210128","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/153537020222700309","article-title":"Hypothalamic histamine neurons activate lipolysis in rat adipose tissue.","volume":"227","author":"Tsuda","year":"2002","journal-title":"Exp Biol Med"},{"key":"R26-11-20210128","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0920-9964(98)00146-7","article-title":"Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro.","volume":"37","author":"Bymaster","year":"1999","journal-title":"Schizophr Res"},{"key":"R27-11-20210128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds.","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"key":"R28-11-20210128","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"R29-11-20210128","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0006-8993(01)02242-9","article-title":"Enhanced leptin transport across the blood-brain barrier by alpha 1-adrenergic agents.","volume":"899","author":"Banks","year":"2001","journal-title":"Brain Res"},{"key":"R30-11-20210128","doi-asserted-by":"crossref","first-page":"789","DOI":"10.4088\/JCP.v67n0513","article-title":"Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.","volume":"67","author":"Henderson","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R31-11-20210128","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects.","volume":"32","author":"Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"R32-11-20210128","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0091-3057(03)00079-0","article-title":"Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake.","volume":"75","author":"Dwyer","year":"2003","journal-title":"Pharmacol Biochem Behav"},{"key":"R33-11-20210128","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.lfs.2007.08.009","article-title":"Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats.","volume":"81","author":"Choi","year":"2007","journal-title":"Life Sci"},{"key":"R34-11-20210128","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.schres.2008.05.011","article-title":"The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.","volume":"103","author":"Lykkegaard","year":"2008","journal-title":"Schizophr Res"},{"key":"R35-11-20210128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.schres.2008.06.006","article-title":"Insulin resistance following continuous, chronic olanzapine treatment: an animal model.","volume":"104","author":"Chintoh","year":"2008","journal-title":"Schizophr Res"},{"key":"R36-11-20210128","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.biopsych.2004.10.023","article-title":"Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats.","volume":"57","author":"Turrone","year":"2005","journal-title":"Biol Psychiatry"},{"key":"R37-11-20210128","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejphar.2007.11.078","article-title":"Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution.","volume":"585","author":"van der Zwaal","year":"2008","journal-title":"Eur J Pharmacol"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004714-200912000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:03:32Z","timestamp":1786039412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-200912000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3181bfe13e","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}